Andrographolide Derivatives for Parenteral Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Andrographolide, a key compound from Andrographis paniculata, has limited water solubility, making it difficult for effective administration beyond oral routes, and existing derivatives face adverse reactions in clinical use for acute viral infections.
Innovation Solution
Development of modified compounds represented by formulas (I) and (II) or their pharmaceutically acceptable salts, which enhance water solubility and are designed for use in treating inflammatory diseases such as pneumonia and upper respiratory tract infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If andrographolide is administered orally, then it can be given to patients, but its water solubility remains poor limiting effective administration
Solution Approach 1:
The patent modifies the chemical structure of andrographolide by introducing hydrophilic groups (such as carboxylic acid groups) at specific positions (C-3, C-16, or C-19) of the andrographolide molecule. This structural parameter change transforms the lipophilic andrographolide into water-soluble derivatives (compounds of formula I and II), enabling parenteral administration while maintaining pharmacological activity.
Solution Approach 2:
The patent creates composite chemical structures by combining the andrographolide core structure with hydrophilic functional groups. The resulting compounds (formula I and II) are composite molecules that integrate the pharmacologically active andrographolide scaffold with water-soluble moieties, achieving both solubility and biological activity.
2Quantity of substance
If existing andrographolide derivatives are used for acute viral infections, then water solubility is enhanced, but adverse reactions occur from time to time
Solution Approach 1:
The patent introduces hydrophilic groups at specific local positions (C-3, C-16, or C-19) of the andrographolide molecule rather than modifying the entire structure. This localized modification enhances water solubility while preserving the core pharmacologically active andrographolide structure, potentially reducing adverse reactions compared to more extensive structural modifications.
Solution Approach 2:
The patent carefully controls the structural parameters of the derivatives by limiting modifications to specific positions with specific hydrophilic groups. This precise parameter control optimizes the balance between water solubility and pharmacological safety, reducing adverse reactions while maintaining efficacy.
Data Source
AI summary
The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.